In vivo and in vitro characterisation of a nonpeptide vasopressin V(1A) and V2 receptor antagonist (YM087) in the rat

European Journal of Pharmacology

Volumn 381, Issue 1, 1999, Pages 23-30

  Risvanis, John ^a   Naitoh, Mareo ^a   Johnston, Colin I ^a   Burrell, Louise M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

(Rat); Nonpeptide; Vasopressin; Vasopressin receptor; YM087

Indexed keywords

CONIVAPTAN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG BINDING; DRUG EFFICACY; FLUID RETENTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; VASOCONSTRICTION;

ADMINISTRATION, ORAL; ANIMALS; BENZAZEPINES; BINDING, COMPETITIVE; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; IODINE RADIOISOTOPES; KIDNEY; KINETICS; LIVER; MALE; MEMBRANES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, VASOPRESSIN; SODIUM; SYSTOLE; URINATION; VASOPRESSINS;

EID: 0032879771     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00530-0     Document Type: Article

References (22)

1. Burrell L.M., Phillips P.A., Stephenson J., Risvanis J., Hutchins A.M., Johnston C.I. Characterization of a novel non-peptide vasopressin V1 receptor antagonist (OPC-21268) in the rat. J. Endocrinol. 138:1993;259-266.
2. Burrell L.M., Phillips P.A., Stephenson J.M., Risvanis J., Rolls K.A., Johnston C.I. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat. Hypertension. 23:1994;737-743.
3. Burrell L.M., Phillips P.A., Risvanis J., Chan R.K., Aldred K.L., Johnston C.I. Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat. Am. J. Physiol. 275:1998;H176-H182.
4. Jard S., Gaillard R.C., Guillon G., Marie J., Schoenenberg P., Muller A.F., Manning M., Sawyer W.H. Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis. Mol. Pharmacol. 30:1986;171-177.
5. Johnston C.I. Vasopressin in circulatory control and hypertension. J. Hypertens. 3:1985;557-569.
6. Johnston C.I., Naitoh M., Risvanis J., Farina N., Burrell L.M. New hormonal blockade strategies in cardiovascular disease. Scand. Cardiovasc. J. 47:1998;61-66. Suppl.
7. 7]AVP: a selective radioligand for V1 vasopressin receptors J. Receptor Res. 9:1989;27-41.
8. Liu J.J., Chen J.R., Buxton B., Johnston C.I., Burrell L.M. Potent inhibitory effect of SR 49059, an orally active non-peptide vasopressin V1a receptor antagonist, on human arterial coronary bypass graft. Clin. Sci. 89:1995;481-485.
9. Michell R.H., Kirk C.J., Billah M.M. Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin. Biochem. Soc. Trans. 7:1979;861-865.
10. Mohr E., Richter D. Vasopressin in the regulation of body functions. J. Hypertens. 12:1994;345-348.
11. Morel A., Lolait S.J., Brownstein M.J. Molecular cloning and expression of rat V1a and V2 arginine vasopressin receptors. Regul. Pept. 45:1993;53-59.
12. Phillips P.A., Abrahams J.M., Kelly J.M., Mooser V., Trinder D., Johnston C.I. Localization of vasopressin binding sites in rat tissues using specific V1 and V2 selective ligands. Endocrinology. 126:1990;1478-1484.
13. Pullan P., Johnston C., Anderson W., Korner P. The role of vasopressin in blood pressure control and in experimental hypertension. Clin. Sci. Mol. Med. 5:1978;251s-254s.
14. Serradeil-Le Gal C., Lacour C., Valette G., Garcia G., Foulon L., Galindo G., Bankir L., Pouzet B., Guillon G., Barberis C., Chicot D., Jard S., Vilain P., Garcia C., Marty E., Raufaste D., Brossard G., Nisato D., Maffrand J.P., Le Fur G. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J. Clin. Invest. 98:1996;2729-2738.
15. 1b vasopressin receptor. J. Biol. Chem. 269:1994;27088-27092.
16. Tahara A., Tomura Y., Wada K., Kusayama T., Tsukada J., Takanashi M., Yatsu T., Uchida W., Tanaka A. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1a and V2 receptor antagonist, in vitro and in vivo. J. Pharmacol. Exp. Ther. 282:1997;301-301.
17. Tahara A., Tomura Y., Wada K., Kusayama T., Tsukada J., Ishii N., Yatsu T., Uchida W., Tanaka A. Binding characteristics of YM087, an AVP receptor antagonist, in rhesus monkey liver and kidney membranes. Peptides. 19:1998;691-696.
18. 4]AVP: an AVP V2 receptor antagonist radioligand Peptides. 12:1991;1195-1200.
19. Wang Y.X., Franco R., Gavras I., Gavras H. Effects of chronic administration of a vasopressin antagonist with combined antivasopressor and antiantidiuretic activities in rats with left ventricular dysfunction. J. Lab. Clin. Med. 117:1991;313-318.
20. Yamamura Y., Ogawa H., Yamashita H., Chihara T., Miyamoto H., Nakamura S., Onogawa T., Yamashita T., Hosokawa T., Mori T. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br. J. Pharmacol. 105:1992;787-791.
21. Yamamura Y., Nakamura S., Itoh S., Hirano T., Onogawa T., Yamashita T., Yamada Y., Tsujimae K., Aoyama M., Kotosai K., Ogawa H., Yamashita H., Kondo K., Tominaga M., Tsujimoto G., Mori T. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J. Pharmacol. Exp. Ther. 287(3):1998;860-867.
22. Yatsu T., Tomura Y., Tahara A., Wada K., Tsukada J., Uchida W., Tanaka A., Takenaka T. Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1a and V2 receptor antagonist, in dogs. Eur. J. Pharmacol. 321:1997;225-230.